Condition
Thrombocytopenia; Drugs
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 4 (2)
Trial Status
Unknown3
Clinical Trials (3)
Showing 3 of 3 trials
NCT05944445UnknownPrimary
The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT
NCT04915287Phase 4UnknownPrimary
Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
NCT04845659Phase 4UnknownPrimary
Avatrombopaq In Patients With Cirrhosis
Showing all 3 trials